LON:CRTX CRISM Therapeutics Interim Earnings Report GBX 10.50 +0.50 (+5.00%) As of 07/15/2026 11:28 AM Eastern ProfileEarnings History CRISM Therapeutics EPS ResultsActual EPS-GBX 2.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACRISM Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACRISM Therapeutics Announcement DetailsQuarterInterimDate9/15/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile CRISM Therapeutics Earnings HeadlinesCRISM Therapeutics Upsizes Oversubscribed Retail Offer to Fund Cancer Drug Delivery TrialsMay 28, 2026 | tipranks.comCRISM Therapeutics Raises Funds for Glioblastoma TrialDecember 15, 2025 | tipranks.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move.July 16 at 1:00 AM | Porter & Company (Ad)CRISM Therapeutics Launches £100,000 Retail Offer to Fund Clinical TrialDecember 10, 2025 | tipranks.comCRISM Therapeutics Secures £1 Million for Phase 2 Glioblastoma TrialDecember 10, 2025 | tipranks.comCRISM Therapeutics Secures Approval for Phase 2 Glioblastoma TrialSeptember 1, 2025 | tipranks.comSee More CRISM Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CRISM Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISM Therapeutics and other key companies, straight to your email. Email Address About CRISM TherapeuticsCRISM Therapeutics (LON:CRTX) is clinical stage company, having developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. CRISM will initiate its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in Q1 2026. For more information please visit: https://www.crismtherapeutics.comView CRISM Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Tesla’s Delivery Surprise Was Big—Earnings Need to Be BiggerWhy Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityApple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before EarningsWhy ASML’s AI Monopoly Is Still Getting StrongerAlphabet’s AI Spending Question Looms Over Q2 EarningsCPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive StocksPlot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger Upcoming Earnings Fifth Third Bancorp (7/17/2026)Truist Financial (7/17/2026)Travelers Companies (7/17/2026)HDFC Bank (7/18/2026)ICICI Bank (7/18/2026)General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
